Changing the Face Of CNS-Disease Treatment
The most recent figures on the impact of CNS-based disease on the global population shows that neurological disorders were the leading cause of disability-adjusted life-years (DALY – or the sum of years of life lived and lost) and the second leading cause of deaths. The absolute number of deaths and DALYs from all neurological disorders combined increased by 39% and 15% respectively between 1990 and 2016.
Dealing With Brain Tumors
Within the umbrella of CNS-based disease, cancer remains a growing concern because of its occurrence and low survivability rates. In the U.S. it is estimated that close to 88,000 patients will be diagnosed with a brain tumor in 2020. Of these 24,000 of these will be malignant gliomas with a 5-year survivability rate of only 36% with treatment. For those with the most common form of primary malignant brain tumors, glioblastoma, the five-year relative survival rate drops to only 6.8%. The annual cost of treatment per patient for the treatment of a malignant glioma diagnosis is approximately $175,000.00. Direct institutional cost for both inpatient and outpatient cases was $80.2 billion in 2015. Indirect costs for secondary issues and quality of life loss add substantially to this number.
Growing Concerns For Dementia
Of equal and growing concern within the CNS-disease umbrella is the dramatic incidence rate for age-related brain diseases such as Parkinson’s, Alzheimer’s, and non-specific dementia. Currently, it is estimated that 5 million Americans are living with Alzheimer’s with this number expected to nearly triple by 2050. More than 10 million people worldwide are living with Parkinson’s. Combine the current cost for the treatment of these two diseases in the U.S. alone exceeds $360 billion per year. Add to this the number of people with other associated CNS-based diseases such as Epilepsy, Stroke, Huntington’s Disease, Multiple Sclerosis, and traumatic brain injury, and the cost both to life and pocketbook are astronomical.
The NeOnc Potential
NeOnc Technologies’ novel therapeutic delivery technology has the ability to dramatically improve both survivability and the economic cost for a wide percentage of these issues. All of our completed studies and ongoing research is pointing to the positive ability of our wrapper molecule and internasal delivery methodology to provide an increase in the effectiveness of the delivered therapeutic to treat the targeted disease. By even a conservative estimate of a 15% increase in effectiveness, the savings in physician and patient cost is significant. The savings of course in quality of life improvement is incalculable.
NeOnc Technologies is dedicated to becoming the industry leader in this method of treatment delivery. As our partnering with pharma-therapeutic manufactures proves the viability of our technology to improve quality of care, we hope to expand our delivery mechanism to an even wider array of therapeutics where our technology can offer enhance outcomes for the millions of patients affected by CNS disease.